These strategies aim to reverse multidrug resistance by degrading oncogenic DUBs or stabilizing tumor-suppressor proteins, thereby providing new research leads and potential translational directions for precision therapy in CRC. This evidence concerns the gene TCHP and colorectal carcinoma.